PCV38 BUDGET IMPACT ANALYSIS OF DABIGATRAN VERSUS VITAMIN K ANTAGONIST IN PATIENTS WITH ATRIAL FIBRILLATION USING ABSORPTION COST DATA FROM HOSPITAL REGIONAL DE CONCEPCION, CHILE

Abstract

Atrial fibrillation (AF) remains as one of the diseases with highest burden for public system. The objective of this work is to estimate the budget impact of Dabigatran versus vitamin K antagonists in patients with AF and labile international normalized ratio (INR), from the specific perspective of the Hospital Regional de Concepción, Chile A 5-year time horizon was used to estimate cost of drugs, disease management, clinical consequences, and treatment related adverse events. Costs were estimated using absorption cost method (A method to build up total production cost including indirect and overhead costs through an absorption rate). Effect of Dabigatran in disease management, clinical consequences and adverse event were estimated directly from results of pivotal trial The expect cost in USD (1 USD = 750 CLP) to treat a labile INR patient with Dabigatran is USD 2,960 per patient/year and with vitamin K antagonist is USD 3,163 per patient/year, saving USD 203 per patient/year. Applying to the prevalent population of the Hospital, the savings per year to the hospital are estimated in USD 681,624. The use of Dabigatran leads to less resource use that can be translated in a reduction of 50 urgency visits per year, 370 GP visits per year, 20 surgeries per year and 200 inpatient day per year in a prevalent population of 3,300 people with labile INR Using Dabigatran to treat AF labile INR patients saves resources in comparison to treat them with standard vitamin K antagonists